News

Les grandes fondations de recherche Parkinson UK et la Michael J. Fox Foundation for Parkinson's Research (MJFF) se sont associées à Neurolixis pour financer un essai de phase 2A de 2 millions de dollars sur les effets cliniques du NLX-112. Le composé a déjà démontré une forte capacité à réduire les mouvements incontrôlés, connus sous le nom de dyskinésie, qui sont présents chez les personnes atteintes de la maladie de Parkinson qui ont été traitées pendant plusieurs années avec de la lévodopa. Entre 40 et 50 % des personnes atteintes de la maladie de Parkinson souffriront de dyskinésie après seulement cinq ans de traitement à la lévodopa.

Le NLX-112 agit en ciblant les neurones du cerveau qui produisent la sérotonine. On pense que ces neurones contribuent au développement de la dyskinésie en convertissant la lévodopa - le principal médicament pris pour la maladie de Parkinson - en dopamine et en la libérant de manière irrégulière. Le NLX-112 stabilise la quantité de dopamine que ces cellules sérotoninergiques libèrent.

La nouvelle étude, dite de Phase 2A, menée par une équipe de l'Institut Karolinska en Suède, va maintenant évaluer si le NLX-112 est bien toléré chez les personnes atteintes de la maladie de Parkinson. L'étude examinera également si le NLX-112 peut réduire la dyskinésie ainsi que certains symptômes non moteurs, tels que la dépression et les troubles du sommeil.

Voir l'annonce de presse officiel.

 

Neurolixis Inc. is delighted to announce the appointment of Dr. Christopher Jankosky, MD, MPH, as a member of its Advisory Board

Dr. Jankosky' career as a neurologist and occupational medicine expert in the U.S. Navy, together with his work in the FDA have given him a profound understanding of both CNS disorders and regulatory aspects of drug develoment. Dr. Jankosky's broad experience as a corporate medical advisor will provide valuable insights and facilitate the advancement of the Neurolixis programs.

See more information concerning Neurolixis' team here.

Neurolixis Inc. offers a warm welcome to Fabienne Herbrecht, as Director of Clinical Development.
Dr. Herbrecht has gained extensive experience of drug development at a clinical level in several large and medium-sized pharmaceutical companies where she managed development, regulatory and clinical programs on drug candidates. Her expertise will be valuable as Neurolixis moves forward with development of its drug pipeline, notably as concerns targeting Parkinson's disease with the Phase 2A clinical candidate, NLX-112.

See more information concerning Neurolixis' management team here.

 

A drug discovery program run by Neurolixis in collaboration with researchers at Jagiellonian University (Krakow, Poland) has identified the first selective serotonin 5 HT1A receptor 'biased agonists' targeting beta-arrestin activation. Serotonin (5-hydroxytryptamine, 5-HT) is a key brain neurotransmitter that acts by activating neuronal receptors such as 5-HT1A. Neurolixis has developed a platform of novel compounds, known as ‘biased agonists’ that preferentially target specific intracellular signaling cascades via 5-HT1A receptors. The new study, reported in the Journal of Medicinal Chemistry, describes novel biased agonists that very selectively and potently activate beta-arrestin, a signaling mechanism at 5-HT1A receptors that is different to that targeted by previous Neurolixis biased agonists that target ERK1/2 phosphorylation. Notably, the beta-arrestin biased agonists exhibited distinct effects in rodent behavioral tests, likely reflecting specific neuronal signaling properties. The discovery may to lead to a new generation of molecules that differentially modulate this important neuronal receptor.

Adrian Newman-Tancredi CEO of Neurolixis commented, “We are excited that our drug discovery program has generated innovative compounds that could be relevant for treatment of central nervous system disorders such as depression or chronic pain.”

See the full publication (open access):
Discovery of novel pERK1/2- or β-Arrestin-Preferring 5-HT1A Receptor Biased Agonists: Diversified Therapeutic-Like vs. Side Effects Profile.
Sniecikowska et al., J Med Chem. 2020 Sep 4. doi: 10.1021/acs.jmedchem.0c00814. PMID: 32883072

 

A new publication on NLX-112 further highlights its potential utility for treatment of dyskinesia (uncontrolled movements), a disturbing side effect of L-DOPA therapy in Parkinson's disease. NLX-112 was tested in parkinsonian macaques, a primate species that is highly predictive of response in human Parkinson's disease patients. When the macaques received NLX-112, their dyskinesia symptoms were  strongly reduced, confirming a previous study carried out in parkinsonian marmosets. Notably, NLX-112 did not interfere with the therapeutic movement facilitation produced by L-DOPA. Taken together, these results provide compelling support for testing NLX-112 in  Parkinson's disease patients. Safe and efficacious treatment of dyskinesia constitutes a clear medical need and NLX-112 could significantly improve the quality of life of Parkinson's disease patients. 

Full publication:  Depoortère et al. Parkinsonism and Related Disorders, vol. 78, p151-157, 2020

La Craig H. Nielsen Foundation, une fondation privée qui soutient la recherche scientifique et aide les patients ayant subi des lésions de la moelle épinière, a accordé une subvention de $ 641,000  pour étudier la capacité du NLX-112 à améliorer la fonction urinaire chez le rongeur dans des modèles de lésions de la moelle épinière. Des travaux expérimentaux seront effectués en collaboration entre Neurolixis, une Jeune Entreprise Innovante accompagnée par la Technopole de Castres Mazamet, et une équipe à la Cleveland Clinic, Ohio, menée par le Dr. Yu-Shang Lee.

Selon le Dr Lee :  “Environ 17 700 patients subissent des lésions de la moelle épinière chaque année aux Etats Unis et plus de 250 000 au niveau mondial. De nombreuses complications résultent de ces lésions, y compris des troubles des voies urinaires et une suractivité de la vessie. Ces complications impactent fortement la qualité de vie des patients et il y a un fort besoin médical pour des traitements efficaces."

Selon Adrian Newman-Tancredi, PhD, DSc, CEO de Neurolixis : “Des études effectués par Neurolixis démontrént que le NLX-112 a une influence prononcée au niveau de la moelle épiniere, induisant l'expression de marqueurs biologiques et d'une activité analgesique. Ces données suggèrent que le NLX-112 possède un mécanisme d'action qui pourrait réduire la dysfonction des voies urinaires."

En plus de tester les effets du NLX-112, le Dr. Lee examinera aussi la synergie potentielle du NLX-112 en combinaison avec l'exercice physique. Si les résultats se montrent prometteurs chez le rongeur, Neurolixis poursuivra le développement du NLX-112 au niveau clinique chez des patients avec des lésions de la moelle épinière.

Voir la description du projet sur le site de la Craig Nielsen Foundation ici.

Neurolixis offers a warm welcome to Mark S. Kleven, PhD, as Director of Operations.

Dr. Kleven has gained extensive experience in several biotech and pharmaceutical companies where he managed in vivo pharmacology programs, prepared FDA-compliant regulatory documents and interacted with funding agencies including NIH and Dept of Defense. His project management expertise will be valuable as Neurolixis increases the scope of its programs in both the EU and the USA by developing clinical candidates targeting Parkinson's disease and Rett syndrome and also in characterizing development candidates from its proprietary drug discovery program.

See more information concerning Neurolixis' management team here.

A new study on NLX-112 tested its effects in marmosets with Parkinson’s-like symptoms. The marmosets had developed the side effect of dyskinesia in response to L-DOPA treatment, in a similar way to many people with Parkinson’s. The results showed that NLX-112 successfully reduced dyskinesia and, crucially, did not significantly reduce the effectiveness of L-DOPA, which many other similar drugs do. When NLX-112 was used on its own (without L-DOPA), it again improved movement problems. These promising results suggest that NLX-112 has potential as a future treatment for not only reducing dyskinesia, but also for improving the movement symptoms of Parkinson’s.

Adrian Newman-Tancredi, CEO of Neurolixis commented, “We are excited that NLX-112 has shown such positive results. If the striking preclinical data are reproduced in clinical trials, NLX-112 could significantly alleviate the troubling dyskinesia that prevent many Parkinson’s patients from performing routine daily tasks, thereby improving their quality of life.”

Full Press Release: Promising drug could treat Parkinson's
Full publication:  Neuropharmacology Vol. 167, 1 May 2020

No alt text provided for this imageNo alt text provided for this imageNo alt text provided for this image

The United States Patent and Trademark Office (USPTO) has just issued a patent on NLX-112 (aka befiradol), a drug developed by Neurolixis for treatment of dyskinesia in Parkinson's disease. The invention is based on a clinical trial which tested sustained release formulations of NLX-112, showing that they avoided side effects of dizziness and nausea. The issuance of the patent (US 10,548,885 B2) protects NLX-112 in the US until 2035. The patent has already issued in the European Union, Canada, Australia and Russia, and is pending in other territories.

Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis commented, “We are delighted that the patent has issued in the US. Movement disorders are a major healthcare challenge, particularly among aging populations in developed nations, and this patent strengthens the commercial prospects of NLX-112 in a major pharmaceutical market.”

Full patent information: WO2016005527A1: Method for treating movement disorders with befiradol

La recherche sur le NLX-112, une molecule en dévéloppement par Neurolixis pour le traitement de la maladie de Parkinson, a été mise en valeur par la Technopole de Castres-Mazamet dans un entretien et un article sur son site web. En particulier, l'entretien attire l'attention sur la récente levée de fonds par Neurolixis auprès du Département de la Défense des Etats Unis
La Technopole de Castres-Mazamet propose du soutien dans la demande de subventions régionales, le recrutement et le networking professionnel.

Voir l'article complet ici.

 

Newsletter

Veuillez activer le javascript sur cette page pour pouvoir valider le formulaire

Follow Neurolixis on: